Crosslink between Temozolomide and PD-L1 immune-checkpoint inhibition in glioblastoma multiforme.

ABSTRACT:

Background

In recent years, PD-1/PD-L1 immune checkpoint inhibitors have improved cancer therapy in many tumor types, but no benefit of immune checkpoint therapy has been found in glioblastoma multiforme (GBM). Based on the results of our earlier work, which showed a reduction of PD-L1 expression in patients treated with temozolomide (TMZ), we aimed to investigate the link between TMZ therapy and the immune control point target PD-L1.

Methods

RNA-sequencing data from de-novo and recurrent glioblastoma were analyzed by AutoPipe algorithm. Results were confirmed either in a cell model by two primary and one established GBM cell line and specimens of de-novo and recurrent GBM. PD-L1 and pathway activation of the JAK/STAT pathway was analyzed by quantitative real-time PCR and we

SUBMITTER: Heynckes S 

PROVIDER: S-EPMC6359796 | biostudies-literature | 2019 Feb

REPOSITORIES: biostudies-literature